Somerset, N.J.-based Catalent, global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it expanded its Singapore facility, which recently received GMP approval from the Health Science Authority, to provide secondary packaging and labeling capabilities. The site is now fully approved for GMP across all its activities, including secondary packaging, label printing, storage, distribution, returns and destruction management.
“Our Singapore facility is a strategic hub for Catalent’s Asia Pacific clinical supply network, with expertise in storage and distribution of clinical supplies,” commented Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Catalent’s Clinical Supply Services business. “Introducing new packaging capabilities, as well as obtaining GMP certification for the facility complements the services provided by our Shanghai site, and allows us to provide more integrated and flexible solutions for customers conducting trials throughout Asia Pacific.”
With uniform systems and facilities in the US, UK, Germany, Singapore and China, and an extended network of over 60 audited depots, the company's clinical supply capacity enables the company to handle a broad range of international compliance and distribution requirements, ultimately reducing customer turnaround time.
The company employs approximately 8,000 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue.
